Vamotinib
Vamotinib (PF-114) is a specific, orally bioavailable tyrosine kinase inhibitor that potently targets both native and T315I-mutant BCR-ABL, inducing apoptosis. It is a valuable research tool for investigating drug-resistant Ph+ leukemias and has been explored in preclinical models of Alzheimer's disease.
Product Specifications
CAS Number
1416241-23-0
Product Name Alternative
Bcr-Abl, BcrAbl, Apoptosis, PF-114, Tyrosine Kinases, TyrosineKinases
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
99.34% (May vary between batches)
Solubility
10% DMSO+90% Saline:2 mg/mL (3.76 mM) ; DMSO:30 mg/mL (56.33 mM)
Smiles
CN1CCN (Cc2ccc (NC (=O) c3ccc (C) c (c3) C#Cc3nnc4ccccn34) cc2C (F) (F) F) CC1
Molecular Formula
C29H27F3N6O
Molecular Weight
532.56
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS2055363-01 0.1 mL
FITC-Linked Polyclonal Antibody to Amylase Alpha 2, Pancreatic (AMY2)
Sign In for Pricing
View Details